In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...
21hon MSNOpinion
Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...
Trump-regeringen har anholdt Mahmoud Khalil, en frontfigur i Gaza-protesterne på Columbia Universitet. Det har udløst vrede ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback